Aurobindo Pharma launches COVID-19 drug Molnupiravir in India

06 Jan 2022 Evaluate

Aurobindo Pharma has launched COVID-19 treatment drug Molnupiravir under the brand name ''Molnaflu'' in India. Molnupiravir is for treatment of adult patients hospitalized with COVID-19, under certain conditions.

Molnupiravir was earlier approved under Emergency Use Authorisation from the Central Drugs Standard Control Organisation.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×